D R Albanus1, J Apitzsch2, Z Erdem3, O Erdem3, F A Verburg1, F F Behrendt1, F M Mottaghy1, A Heinzel4. 1. Department of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany. 2. Department of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany; Department of Diagnostic and Interventional Radiology, University of Gießen and Marburg, Baldingerstraße, 35043 Marburg, Germany. 3. Department of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany; Department of Radiology, Medical Faculty of Bulent Ecevit University, Practice and Research Hospital of Bulent Ecevit University; 67600, Kozlu, Esenköy, Zongludak, Turkey. 4. Department of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany; Institute of Neuroscience and Medicine (INM4), Research Centre Jülich, Germany. Electronic address: aheinzel@ukaachen.de.
Abstract
PURPOSE: To compare and outline the beneficial skills of combined (68)Ga-DOTATATE positron emission tomography (PET) with concurrent contrast enhanced X-ray computed tomography (ceCT) against stand-alone ceCT in 54 patients with neuroendocrine tumours (NET). METHODS: Patients with histologically confirmed NET and available follow-up of at least 6 months (median 12.6 months; range 6.1-23.2) were included. PET/CT and ceCT images were initially analyzed separately by two blinded nuclear medicine physicians and two radiologists, respectively. In a second step all four physicians reviewed all detected lesions together reaching a consensus-grading for PET/ceCT. The results were then compared to the reference standard consisting of clinical follow-up data. RESULTS: With regard to true positive lesions, PET/ceCT vs. stand alone ceCT detected 139 vs. 48 bone-lesions, 106 vs. 71 lymph node metastases and 26 vs. 26 pulmonary lesions. On a per-patient basis, PET/ceCT achieved a higher sensitivity (100% vs. 47%) and specificity (89% vs. 49%) for bone lesions than ceCT. For lymph nodes the effect was similar (sensitivity 92% vs. 64% and specificity 83% vs. 59%). For the detection of pulmonary lesions the sensitivity was identical (100%) while specificity of PET/ceCT was superior to ceCT-alone (95% vs. 82%). CONCLUSION: In summary, the use of (68)Ga-DOTATATE PET/ceCT leads to an increase in sensitivity and specificity in the detection of extra-hepatic NET metastases compared to stand-alone ceCT. Therefore, (68)Ga-DOTATATE PET/ceCT should be the imaging modality of choice in patients with NET.
PURPOSE: To compare and outline the beneficial skills of combined (68)Ga-DOTATATE positron emission tomography (PET) with concurrent contrast enhanced X-ray computed tomography (ceCT) against stand-alone ceCT in 54 patients with neuroendocrine tumours (NET). METHODS:Patients with histologically confirmed NET and available follow-up of at least 6 months (median 12.6 months; range 6.1-23.2) were included. PET/CT and ceCT images were initially analyzed separately by two blinded nuclear medicine physicians and two radiologists, respectively. In a second step all four physicians reviewed all detected lesions together reaching a consensus-grading for PET/ceCT. The results were then compared to the reference standard consisting of clinical follow-up data. RESULTS: With regard to true positive lesions, PET/ceCT vs. stand alone ceCT detected 139 vs. 48 bone-lesions, 106 vs. 71 lymph node metastases and 26 vs. 26 pulmonary lesions. On a per-patient basis, PET/ceCT achieved a higher sensitivity (100% vs. 47%) and specificity (89% vs. 49%) for bone lesions than ceCT. For lymph nodes the effect was similar (sensitivity 92% vs. 64% and specificity 83% vs. 59%). For the detection of pulmonary lesions the sensitivity was identical (100%) while specificity of PET/ceCT was superior to ceCT-alone (95% vs. 82%). CONCLUSION: In summary, the use of (68)Ga-DOTATATE PET/ceCT leads to an increase in sensitivity and specificity in the detection of extra-hepatic NET metastases compared to stand-alone ceCT. Therefore, (68)Ga-DOTATATE PET/ceCT should be the imaging modality of choice in patients with NET.
Authors: Mythili P Pathipati; Thomas K Yohannan; Lu Tian; Kathleen Hornbacker; Jalen A Benson; Gerald J Berry; Natalie S Lui; Pamela L Kunz; Sukhmani K Padda Journal: Lung Cancer Date: 2021-01-23 Impact factor: 5.705
Authors: Anne-Leen Deleu; Annouschka Laenen; Herbert Decaluwé; Birgit Weynand; Christophe Dooms; Walter De Wever; Sander Jentjens; Karolien Goffin; Johan Vansteenkiste; Koen Van Laere; Paul De Leyn; Kristiaan Nackaerts; Christophe M Deroose Journal: EJNMMI Res Date: 2022-05-07 Impact factor: 3.434